Literature DB >> 29292530

Apathy in idiopathic normal pressure hydrocephalus: A marker of reversible gait disorders.

Gilles Allali1,2, Magali Laidet1, Stéphane Armand3, Arnaud Saj1, Paul Krack1, Frédéric Assal1.   

Abstract

OBJECTIVE: Apathy-the most common behavioral disturbance in idiopathic normal pressure hydrocephalus (iNPH)-is associated with poor gait, but the role of apathy on gait improvement after cerebrospinal fluid (CSF) tapping has not been studied yet. This study aims to compare gait improvement after CSF tapping in iNPH patients with and without apathy.
METHODS: Stride time variability (STV), a marker of higher level of gait control, was measured in 33 iNPH patients (78.4 ± 5.7 years; 36.4% women) with an optoelectronic system during usual walking (single task) and during walking while dual tasking of counting and verbal fluency before and 24 hours after CSF tapping. Apathy was defined by a score ≥14 on the Starkstein apathy scale.
RESULTS: Apathy was present in 60.6% of patients. Cerebrospinal fluid tapping led to greater improvement of STV (ie, decrease) during dual-task walking (and more specifically categorical verbal fluency) in apathetic compared to nonapathetic patients (-44.7 ± 58.1% versus +4.24 ± 67.6%, respectively; P = .040), even after adjusting for age and depressive symptoms. More severe apathy was correlated with better STV improvement while dual tasking (categorical verbal fluency) after CSF tapping (r = -0.412; P-value = 0.021), while it was not correlated with improvement on executive tests.
CONCLUSIONS: Our findings suggest that the presence of apathy is a predictor of better outcomes of gait disorders after CSF tapping in patients with iNPH.
Copyright © 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  apathy; dual tasking; executive functions; gait disorders; normal pressure hydrocephalus

Mesh:

Substances:

Year:  2018        PMID: 29292530     DOI: 10.1002/gps.4847

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  5 in total

1.  Structural volumetry in NPH diagnostics and treatment-future or dead end?

Authors:  Aleš Vlasák; Petr Skalický; Arnošt Mládek; Jiří Vrána; Vladimír Beneš; Ondřej Bradáč
Journal:  Neurosurg Rev       Date:  2020-01-24       Impact factor: 3.042

2.  Frontal Behavior Syndromes in Idiopathic Normal Pressure Hydrocephalus as a Function of Alzheimer's Disease Biomarker Status.

Authors:  Madison Niermeyer; Chad Gaudet; Paul Malloy; Irene Piryatinsky; Stephen Salloway; Petra Klinge; Athene Lee
Journal:  J Int Neuropsychol Soc       Date:  2020-05-20       Impact factor: 2.892

3.  Guidelines for Management of Idiopathic Normal Pressure Hydrocephalus (Third Edition): Endorsed by the Japanese Society of Normal Pressure Hydrocephalus.

Authors:  Madoka Nakajima; Shigeki Yamada; Masakazu Miyajima; Kazunari Ishii; Nagato Kuriyama; Hiroaki Kazui; Hideki Kanemoto; Takashi Suehiro; Kenji Yoshiyama; Masahiro Kameda; Yoshinaga Kajimoto; Mitsuhito Mase; Hisayuki Murai; Daisuke Kita; Teruo Kimura; Naoyuki Samejima; Takahiko Tokuda; Mitsunobu Kaijima; Chihiro Akiba; Kaito Kawamura; Masamichi Atsuchi; Yoshihumi Hirata; Mitsunori Matsumae; Makoto Sasaki; Fumio Yamashita; Shigeki Aoki; Ryusuke Irie; Hiroji Miyake; Takeo Kato; Etsuro Mori; Masatsune Ishikawa; Isao Date; Hajime Arai
Journal:  Neurol Med Chir (Tokyo)       Date:  2021-01-15       Impact factor: 1.742

4.  Feasibility of action observation effect on gait and mobility in idiopathic normal pressure hydrocephalus patients.

Authors:  Htet Htet Hnin; Sunee Bovonsunthonchai; Theerapol Witthiwej; Roongtiwa Vachalathiti; Rattapha Ariyaudomkit
Journal:  Dement Neuropsychol       Date:  2021 Jan-Mar

5.  CSF tap test in idiopathic normal pressure hydrocephalus: still a necessary prognostic test?

Authors:  Alessandra Griffa; Giulia Bommarito; Frédéric Assal; Maria Giulia Preti; Rachel Goldstein; Stéphane Armand; François R Herrmann; Dimitri Van De Ville; Gilles Allali
Journal:  J Neurol       Date:  2022-05-22       Impact factor: 6.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.